Skip to main
  1. Stocks
  2. Septerna Inc
  3. Forecast
SEPN

Septerna Inc (SEPN) Stock Forecast & Price Target

Septerna Inc (SEPN) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Septerna is viewed favorably because its lead oral PTH1R agonist SEP-479 has shown a ~3-4 day half-life, a safety profile that appears structurally distinct from discontinued SEP-786, and Phase 1 SAD/MAD data in healthy volunteers remains on track for 1Q27, which could de-risk a large hypoparathyroidism opportunity. The company also has multiple additional shots on goal, including SEP-204 for Graves’ disease/TED and SEP-631 for mast-cell driven diseases, both supported by encouraging preclinical or early clinical data and the potential for meaningful platform validation across endocrinology and immunology. Financially, Septerna ended the quarter with $565.2MM in cash and cash equivalents, with runway into 2029 and meaningful R&D support from the Novo Nordisk partnership, while reported losses were narrower than expected.

Bears say

Septerna is a clinical-stage biotechnology company with no approved products, so its value depends heavily on uncertain trial outcomes, regulatory clearance, and eventual commercial adoption across endocrinology, immunology and inflammation, and metabolic disease. The disclosed Phase 1 safety issue in SEP-786, including two unanticipated severe Grade 3 unconjugated bilirubin events that forced dosing discontinuation, highlights platform risk and suggests the company may face further delays, added development costs, or setbacks in future programs such as SEP-631 and other pipeline assets. It also faces significant competitive and commercial pressure, while the risk of a dilutive equity offering could further weaken shareholder returns if funding needs rise before meaningful clinical progress is achieved.

Septerna Inc (SEPN) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.

Septerna Inc (SEPN) Analyst Forecast & Price Prediction

Get the latest Septerna Inc (SEPN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Septerna Inc (SEPN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Septerna Inc (SEPN) Forecast

Analysts have given Septerna Inc (SEPN) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Septerna Inc (SEPN) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Septerna Inc (SEPN)


Septerna Inc (SEPN) Analyst Forecast & Price Prediction

Get the latest Septerna Inc (SEPN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Septerna Inc (SEPN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SEPN stock data and trends